Odyssey Therapeutics (NASDAQ:ODTX) Now Covered by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Odyssey Therapeutics (NASDAQ:ODTX) in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage set a “buy” rating and a $40.00 price target on the stock. HC Wainwright‘s target price indicates a potential upside of 111.86% from the company’s current price.

Several other equities research analysts have also issued reports on ODTX. UBS Group assumed coverage on shares of Odyssey Therapeutics in a report on Monday, October 12th. They issued a “buy” rating and a $27.00 target price for the company. Raymond James Financial initiated coverage on shares of Odyssey Therapeutics in a report on Thursday, October 8th. They set an “outperform” rating and a $42.00 price target on the stock. Weiss Ratings started coverage on shares of Odyssey Therapeutics in a research report on Tuesday, August 11th. They issued a “sell (d+)” rating for the company. Finally, JPMorgan Chase & Co. increased their price objective on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $34.67.

Odyssey Therapeutics Stock Performance

NASDAQ ODTX opened at $18.88 on Friday. Odyssey Therapeutics has a 52 week low of $15.10 and a 52 week high of $29.05. The stock has a 50-day moving average of $21.31.

Odyssey Therapeutics (NASDAQ:ODTX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) earnings per share (EPS) for the quarter. On average, equities analysts predict that Odyssey Therapeutics will post -6.08 EPS for the current fiscal year.

Institutional Trading of Odyssey Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ODTX. Citadel Advisors LLC purchased a new position in shares of Odyssey Therapeutics in the second quarter worth $4,162,000. State Street Corp purchased a new position in Odyssey Therapeutics during the second quarter valued at $1,477,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Odyssey Therapeutics during the second quarter valued at $601,000.

About Odyssey Therapeutics

Odyssey Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, functional genomics, and experimental drug discovery to identify therapies directed at disease-driving biological pathways.

Its research programs are centered primarily on small-molecule medicines and other targeted approaches intended to modulate the immune system or address vulnerabilities in cancer cells.